Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Coffee first.

Why is BPRG not heading higher? Look at SEO...shame on you, BPRG

Glad i got both, what a day on SEO, EVO forecast is 20p... DYOR.

why on earth are you peeps droning on about damages from SEO? TRADE the damned shares. all the while volumes are so huge on both shares there is a good chance you will be luckier than the next guy who buys/sells.

i lost nearly 3k on this one, but have very nearly got it back from SEO.

Amities / bonsoir/ salut . en brevite..>.Despite what may appear a glistening flow of products in the pipeline l find very little attraction in this company in its own right.To my mind it flatters only to deceive .lts board and senior management are at best stationary,uninspiring, vaccilitating and ,and have found to be utterly wanting on a number of occasions . Personally l am surprised it has even survived the 60p level what with the volume of short held positions . Those who run the book on this ex city darling do not hold it in great esteem.One of whom is known to me rates them 68p tops ! Like my self recently the s/p has been playing the 62p -73p sidestep boogie and prior to that it was a 62p-75p . Now regardless of it breaking out of these trading parameters and achieving the dizzy heights of 80p last week i believe all things left to themselves it would be back to the 62 level within a few weeks . lt is one of those shares that over the years has fully proven the adage that all that glitters is not gold .Personally i would never pay more than 62p for this stock . Now having said all that they have proven without doubt in a prolonged High court action that ownership of a family of patents regarding intelectual property was undoubtadly infriged upon by SEO. Talk of 15m in punitives damages and incurred associated legal costs are on the cards. Now SEO have a mere derisory 800k in the bank and under usual circumstances such a court case would have sunk them without trace . A Phyric victory for BPRG you would agree and pretty typical to be honest of the way business is done at BPRG . But as seldom happens in such scenarios - Father luck seemingly makes an appearance ; and SEO announce they also have seemingly commercial interlectual properties of thier own in RF tec and are in trials with a number of retail giants . . A technology that could yield untold millions if deals are struck with their suitors like Asda and through them to Wal Mart . C'est le vie ! Now irrespective of how revolutinary and marvelous this RF tec proves to be it DOES not erradicate the problem of the small problem of SEO stumping up 15 million quid !! And pretty sharpish,, .. .l cannot UNDERESTIMATE the importance of SEO finding such monies . .But how ? Well as it happens BPRG {whose legal costs were paid by thier insurers} are in a position, what with 20m in liquid cash, to settle the small problem of Seo's court costs and in return for that and punitive damages a 20% interest in SEO would seem reasonable. ...Now thats a deal that may allow BPRG to progress ( pun unintended) and Seo to survive. C'est marche ou creve ,, Personally i dont believe CEO Balchin is up to the job and as for the addition of a Durlacher man to the SEO board cuts no ice with me and , as such, l remain unimpressed . Does anyone know of a successful lPO or company backed by DUC ,? LOL ..As for BPRG without such an interest in SEO i see very little material change to thier chequered past for the immediate future. ,,But it goes without saying this is merely my personal input and i wish only "good Luck " to all holders of BPRG ,,,,,a'bientot . bonne chance ! @+ J

Bonne jour, Jamie,

I Bought 120,000 SEO this morning, will SEO be another 500k + for you, LOL

Alors !!! But of course. . ,,,lol Gauling isnt it ? lol. Wouldnt touch BPRG tho Roly.Not with the proverbial bargepole ,,,Re; SEO Yep you certainly dont need a weather vane to know which way the wind is blowin ,? Amities ,,,@= J,,,

Frenchi that leaves more for the rest of us!! Up again to-day!!!

Fred are you still holding BPK, i sold half at 547p, and holding the other half for the div, do you hold SEO?

Sold BPK at 540 including dealing charges at a loss. Bought SEO at 5.25 but also holding BPRG. Will continue to hold both. But may dive back into BPK nearer next results, still think it has the potential for growth, but the rate is going to slow down for a bit.


Would like a bit more voulume on BPRG

.

9 and 38day averages look O.K. to send price to 80p by friday,then everyone will probably sell off.Why is there so little faith in management?BRPG looks ready to sign a major deal and seem much better prepared financially than SEO.Did Bprg organise the case specifically to get a 20% interst in Seo ?Seems incredibly devious,but one way of warning potential competitors to watch out.

BioProgress PLC
10 February 2005


Press Release 10 February 2005




BioProgress plc
('BioProgress' or 'the Company')

BioProgress signs contract with Custom Pharmaceuticals for new UK
pharmaceutical film manufacturing facility and appoints Callisto Consulting to

progress US and European medicines product license applications



BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery
mechanisms for the pharmaceutical oral dosage markets, announces that it has now
executed an agreement with Custom Pharmaceuticals Limited ('Custom') to install
a film manufacturing line in Custom's (
www.custompharm.com
) new pharmaceutical
contract manufacturing facility currently being built near Brighton, in the
south of England. This follows the initial Letter of Intent announcement on 9
November 2004.



Internal modification and upgrading of the existing building started in December
2004 and is expected to be completed in approximately three months. The film
casting line, purchased from Valence Technology BV in August 2004, is being
refurbished and will then be delivered and installed along with the other
relevant equipment. The facility and equipment is specified to the latest EC
and US FDA pharmaceutical standards.



The production of BioProgress pharmaceutical grade films in the new plant for
its SOLULEAVESTM, WAFERTABTM and FOAMBURSTTM technologies, as well as films
required for the SWOLLOTM, TABWRAPTM and NROBETM technologies is planned to be
in full production by August 2005.



Nigel Richardson, Chairman of Custom Pharmaceuticals Limited, said: 'The more we
have worked with the team at BioProgress, the more excited we have become by the
potential of their innovative technology. We are an established and experienced
medicine manufacturer and our technical team have already spent time in the
BioProgress Tampa film facility, so we are confident we have all the resources,
expertise and qualified personnel to operate the new pharmaceutical film line to
the highest international standards. The BioProgress LOCUM business model makes
sense for all concerned and we are looking forward to a long and fruitful
relationship with BioProgress.'



BioProgress also announces the appointment of Callisto Consulting, a specialist
UK based regulatory agency, which will assist in developing Drug Master Files
which contain all the necessary data on individual product performance required
by the regulatory authorities. Callisto will coordinate the regulatory testing
and application procedures necessary for BioProgress to apply for US and
European Medicine Licences for the SOLULEAVESTM, WAFERTABTM and FOAMBURSTTM
products currently under development. These new products incorporate off-patent
generic drugs which can be sold in the consumer, prescription and veterinary
medicine markets. Callisto estimates that the regulatory process for licensing
generic compounds in a new delivery form can take about a year in the United
States and slightly longer in Europe. There is also however increasing interest
from major drug manufacturers in investigating the use of BioProgress
technologies with their patented drugs.



Graham Hind, Chief Executive of BioProgress, said: 'The signing of these
contracts has moved BioProgress another step closer to the global
commercialisation of our technology. Later this year our customers and
Shareholders will be able to visit the site in Brighton which we believe will be
the first cGMP pharmaceutical film manufacturing facility in Europe and one of
the most 'state-of-the-art' in the world. With our existing Tampa facility, we
anticipate that we will be able to satisfy the demand for all our pharmaceutical
films as our technologies are commercialised.



'In addition to the films needed for our dosage form technologies like TABWRAP
TM, the market for thin edible films continues to develop rapidly. Very soon we
shall have prescription medicines utilising edible film strips giving benefits
of fast absorption into the body combined with ease of administration. Our
recent R&D work on such formulations has gone well and the appointment of
Callisto Consulting will further shorten our time to market. When this is
linked with our unique patent portfolio, we believe BioProgress is in a strong
position to be the leader and manufacturer of first choice in this fast growing
new pharmaceutical market sector.'



- Ends -

Here is some of the news we have been waiting for.


BioProgress to build film manufacturing line in Custom Pharmaceuticals plant
AFX


LONDON (AFX) - BioProgress PLC said it will install a film manufacturing line in Custom Pharmaceuticals Ltd's contract manufacturing facility currently being built near Brighton.

A letter of intent to that effect was announced in Nov 2004.

Internal modification and upgrading of the existing building started in Dec 2004 and is expected to be completed in approximately three months.

The film casting line, purchased from Valence Technology BV in Aug 2004, is being refurbished and will then be delivered and installed along with the other relevant equipment, BioProgress said.

The production of BioProgress pharmaceutical grade films in the new plant is planned to start before August, it added.

BioProgress provides delivery mechanisms for the pharmaceutical oral dosage markets.

newsdesk@afxnews.com

lam



I think it should move quickly back up 100p

BioProgress PLC
11 February 2005


Press Release 11 February 2005




BioProgress plc

("BioProgress" or "the Company")

New patent granted



BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery
mechanisms for the pharmaceutical oral dosage markets, announces today that
another of its pending patents has now been granted.



The patent relates to a new type of capsule configuration, where the walls of
the capsule are comprised of several layers of laminated film, each of which can
be designed to dissolve at a different rate or time. This means the capsule can
be specifically programmed to deliver its contents at a precise time or site in
the body or, for non ingestible applications to, for example, deliver the
capsule content at a precise time in a laundry or dishwasher cycle.



Graham Hind, Chief Executive Officer of BioProgress, said: "We have over eighty
patents in application or granted across a wide spectrum of applications for our
technologies. As more of our extensive patent application portfolio becomes
granted patents it increasingly strengthens our position in being able to offer
innovative, protected solutions that can add significant value to major global
brands and businesses. "

Looks very good, you wont need the likes of Asda to help you sell something like that. Just think of the other applications, especially medicene, treatments of stomach and bowel complaints would be better served, not that I have any!

Looking better this now.

Even more good news.


New patent granted
BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the pharmaceutical oral dosage markets, announces today that another of its pending patents has now been granted in Europe.
The patent relates to a new type of capsule configuration, where the walls of the capsule are comprised of several layers of laminated film, each of which can be designed to dissolve at a different rate or time. This means the capsule can be specifically programmed to deliver its contents at a precise time or site in the body or, for non ingestible applications to, for example, deliver the capsule content at a precise time in a laundry or dishwasher cycle.
Graham Hind, Chief Executive Officer of BioProgress, said: We have over eighty patents in application or granted across a wide spectrum of applications for our technologies. As more of our extensive patent application portfolio becomes granted patents it increasingly strengthens our position in being able to offer innovative, protected solutions that can add significant value to major global brands and businesses.
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. This announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Companys filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.
Enquiries:
For further information, contact us.
Notes to editors:
BioProgress listed on AIM in May 2003 and on NASDAQ in October 2004, and is engaged in the research, development, and design of patented encapsulation systems that use water soluble and biodegradable films for the dietary supplement, pharmaceutical and other sectors. The Companys portfolio comprises over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. BioProgress aims to provide a cost effective and animal-free encapsulation process for pharmaceutical drugs in liquids, tablets and powders, thereby addressing the needs of the entire market for oral dosage forms while providing novel delivery mechanisms not possible with traditional processes.
The Company has also developed patented and licensed the worlds first flushable ostomy pouch that offers a newly enhanced quality of life not previously possible for the end user. Market research shows the global ostomy market to be worth $1 billion annually.
The Companys business model provides it with several significant revenue streams including sales of encapsulating machines and film, plus licence and fees for research development services

Very quiet on this thread considering this am's rise!

I'm a long term holder but have also been in and out successfully many times. Get the feeling that we might have said goodbye to the sixties, if not the seventies.

What do all you expert chartists think?

Good luck to all holders.

Madison: I think today's close (EOW) will be key...if it holds hereabouts then next stop a 1. We might also start to see a lot of heavy short positions being closed as well and that would give a SP push. We will see. jgt